Prednisone withdrawal, in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study

Transplantation

Volumn 68, Issue 12, 1999, Pages 1865-1874

  Ahsan, Nasimul ^f   Hricik, Donald ^a   Matas, Arthur ^b,f   Rose, Stephen ^f   Tomlanovich, Stephen ^c   Wilkinson, Alan ^d   Ewell, Marian ^f   McIntosh, Matthew ^f   Stablein, Donald ^f   Hodge, Ernest ^f   Hayes, Daniel ^f   Gores, Paul ^f   Cohen, David ^f   Gonwa, Thomas ^f   Brinler, Karl ^f   Harland, Robert ^f   Neylan, John ^f   Pescovitz, Mark ^f   Wynn, James ^f   C Yang, Harold ^f   Bennett, William ^f   Copley, John ^f   Dunn, John ^e   Tomlanovich, Steve ^c   Chan, Lawrence ^f   Bertolatus, J Andrew ^f   Weir, Mathew ^f   Mendez, Robert ^f   Pirsch, John ^f   Helderman, J Harold ^f   more..

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT;

EID: 0033611123     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912270-00009     Document Type: Conference Paper

References (55)

1. Hricik DE, Schulak JA. Corticosteroid withdrawal after renal transplantation in the cyclosporine era. BioDrug 1997; 8: 139.
2. Flechner SM, Kerman RH, Van Buren CT, Epps L, Kahan BD. The use of cyclosporine in living-related renal transplantation: donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38: 685.
3. Stratta RJ, Amburst MJ, Oh CS, et al. Withdrawal of steroid immunosuppression in renal transplant patients. Transplantation 1988; 45: 323.
4. Schulak JA, Mayes JT, Moritz CE, Hricik DE. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990; 49: 327.
5. Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53.
6. Tejani A, Butt KMH, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation 1989; 20: 11.
7. Reisman L, Lieberman KV, Burrows L, Schanzer H. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76.
8. Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232.
9. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353.
10. Hariharan S, Schroeder TJ, Weiskittel P, et al. Prednisone withdrawal in HLA identical one haplotype-matched live-related and cadaver renal transplant recipients. Kidney Int 1993; 43 (suppl): S30.
11. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 49: 76.
12. Brown MW, Forwell MA. Rejection reaction after stopping prednisolone in kidney-transplant recipients taking cyclosporine. N Eng J Med 1986; 314: 183.
13. Cristinelli L, Brunori G, Setti G, et al. Withdrawal of methylprednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc 1987; 19: 2021.
14. Hricik DE, O'Toole M, Schulak JA, Herson J. Steroid-free, cyclosporine-based immunosuppression after renal transplantation: a meta analysis of controlled trials. J Am Soc Nephrol 1993; 4: 1300.
15. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
16. Tricontentinal Mycophenolate Mofetil Renal Transplant Study Group. A blinded, randomized clinical trial of mycophenolate for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
17. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for the prevention of acute rejection. Lancet 1995; 1: 1321.
18. Halloran P, Mathew S, Tomlanovich S, et al. for the International Mycophenolate Mofetil Renal Transplant Study Group. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in the prevention of rejection. Transplantation 1997; 63: 39.
19. Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. Transplantation 1998; 65: 235.
20. Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722.
21. Neylan JF for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64: 1277.
22. Cho S, Hodge E, Navarro M, and the International Mycophenolate Mofetil Renal Study Groups. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. Transplant Proc 1999; 31: 322.
23. Kobashigawa J, Miller L, Renlund D, et al. for the Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507.
24. Solez K, Axelsen RA, Benefiktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44 (2): 411.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
27. Greenwood M. The natural duration of cancer. Reports of Public Health and Medical Subjects, vol 33. London: Her Majesty's Stationery Office, 1926.
28. Cox DR. Regression models and life tables (with discussion). J Royal Statistical Soc 1972; B34: 187.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121.
30. Wald A. Sequential analysis. New York: John Wiley, 1947.
31. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal allograft patients treated with cyclosporine. Transplant Proc 1988; 20 (suppl 3): 121.
32. Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomized controlled trial of steroid withdrawal in renal transplant patients receiving triple immunosuppression. Lancet 1996; 1: 643.
33. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Canadian Multicenter Transplant Study Group. Can Med Assoc J 1992; 147: 645.
34. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61: 1038.
35. Flechner SM, Kerman RH, Van Buren CT, et al. The use of cyclosporine in living-related renal transplantation: donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38: 685.
36. O'Connell P, D'Apice A, Walker R, et al. Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone. Transplant Proc 1988; 20: 11.
37. Walker RG, D'Apice AJF, Powell HR, et al. Triple low-dose immunosuppression with cessation of steroids in pediatric renal transplantation. Transplant Proc 1988; 20: 7.
38. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300.
39. Gulanikar AC, Belitsky P, MacDonald AS, et al. Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990.
40. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53.
41. Albert FW, Schmidt U. Cyclosporine therapy with or without steroids in cadaveric kidney transplantation - a prospective randomized one-center study. Transplant Proc 1987; 17: 2669.
42. Thiel G, Harder F, Loertscher R, et al. Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Transplant Proc 1984; 16: 1187.
43. Johnson RWG, Mallick NP, Bakran A, et al. Cadaveric renal transplantation without maintenance steroids. Transplant Proc 1989; 21: 1581.
44. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation - clinical predictors of outcome. Transplantation 1992; 53: 41.
45. Kupin W, Venkat WW, Goggins M, et al. Improved outcome of steroid withdrawal in mycophenolate mofitil-treated primary cadaver renal transplant recipients. Transplant Proc 1999; 31: 1131.
46. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23: 1363.
47. Ponticelli C, Tarantino A, Montagnino G. Controlled trials with cyclosporine in kidney transplantation. Transplant Proc 1994; 26: 2490.
48. Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294.
49. Ghandour FZ, Knauss TC, Mulligan DC, et al. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clin Transplantation 1997; 11: 395.
50. Hricik DE, Seliga RM, Fleming-Brooks S, et al. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Clin Transplant 1995; 9: 419.
51. Grinyo JM, Gil-Vernet S, Seron D, et al. Steroid withdrawal in myophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63: 1688.
52. Kupin W, Venkat KK, Goggins M. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients. Transplant Proc 1999; 31: 1131.
53. Lebranchu Y for the M55002 Study Group. Comparison of two corticosteroid regimens in combination with Cellcept and cyclosporine A for prevention of acute allograft rejection: 12-month results of a double-blind, randomized, multicenter study. Transplant Proc 1999; 31: 249.
54. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64 (9): 1277.
55. Marcussen N, Olsen TS, Benedictsson H, Racusen L, Solez K. Reproducibility of the Banff classification of renal allograft pathology: inter- and intraobserver variation. Transplantation 1995; 60: 1083-89.